Atlas Trials

Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations

Clinical trial NCT01811667 · COMPLETED

Trial details

NCT number
NCT01811667
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Cardiovascular Abnormalities
Start date
2012-05-01
Primary completion
2016-01-01
Enrollment
19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.